AQST catalysts and FDA events, page 2.
Updated Snapshot 20261116T222116ZBuilt
The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on AQST PDUFA dates and upcoming catalysts. This page continues the list.
Past catalysts and FDA decisions (continued)
| Date | Drug | Company | Event | Indication | Status | Source |
|---|---|---|---|---|---|---|
| Oct 2024Month disclosed | — | AQST | Topline readout | — | Met primary endpoint | SEC Form 10-Q |
| Jun 2024Month disclosed | Anaphylm™ (dibutepinephrine) | AQST | Topline readout | — | Positive | SEC Form 10-Q |
| April 29, 2024 | Libervant® (diazepam) | AQST | FDA approval | — | Approved | SEC 8-K Exhibit 99.1 |
| April 26, 2024 | AQST-108 | AQST | FDA approval | — | Approved | SEC 8-K Exhibit 99.1 |
| Aug 2022Month disclosed | Libervant® (diazepam) | AQST | FDA approval | — | Approved | SEC 8-K Exhibit 99.1 |
| November 22, 2019 | Exservan (riluzole) | AQST | FDA approval | — | Approved | openFDA Drugs@FDA |
Every catalyst is quoted from AQST’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.